KALAHealthcare · BiotechnologyKALA Stock Forecast: Kala Bio, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 22 Aug 2026 — in the weakest quartile.
KALA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Kala Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (90): Smaller than most of the companies we track.
Value (2): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
KALA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KALA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 17 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Sept 2025 | Oppenheimer | Maintains | Outperform | — |
| 8 Sept 2025 | Mizuho | Initiates | Outperform | — |
| 11 July 2025 | Ladenburg Thalmann | Initiates | Buy | — |
| 2 June 2025 | Oppenheimer | Assumes | Outperform | $15 |
| 23 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Aug 2024 | Oppenheimer | Reiterates | Outperform | — |
| 17 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 Apr 2024 | Oppenheimer | Reiterates | Outperform | — |
| 17 Nov 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Apr 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KALA appears on the weeks it earns a place.
KALA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Kala Bio, Inc. (KALA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 11.4×
- Price / sales
- —
- Price / book
- 0.1×
- EV / EBITDA
- −0.2×
Cheaper than 56% of US stocks
Cheaper than 91% of US stocks
Cheaper than 62% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −238.7%
- Return on assets
- −69.3%
- Dividend yield
- —
Higher than 6% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
KALA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Kala Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about KALA stock
Is KALA stock a buy right now?
Of the 1 analysts covering Kala Bio, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kala Bio, Inc. 17 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KALA?
As at 22 Aug 2026, Kala Bio, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).
What is the KALA stock forecast for 2030?
No analyst covering Kala Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KALA are extrapolating price history, which says nothing about the business.
How has KALA stock performed over the past year?
Kala Bio, Inc. returned -99.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Kala Bio, Inc. do?
Kala Pharmaceuticals, Inc. (trading as KALA BIO, Inc.) is a clinical-stage biopharmaceutical company focused on developing therapeutics for rare and severe eye diseases.
About Kala Bio, Inc.
Kala Pharmaceuticals, Inc. (trading as KALA BIO, Inc.) is a clinical-stage biopharmaceutical company focused on developing therapeutics for rare and severe eye diseases. The company utilizes proprietary nanoparticle-based mucus penetrating particles technology in its research pipeline. Its lead clinical candidate, KPI-012, a human mesenchymal stem cell secretome therapy, was evaluated in the Phase 2b CHASE trial for persistent corneal epithelial defect, though the trial did not achieve its primary endpoints. The company also has preclinical programs including KPI-014 for rare inherited retinal diseases. Recently, Kala Pharmaceuticals has pursued a strategic shift by entering into an exclusive license agreement for Researgency, a proprietary AI infrastructure platform designed for biotech research and development workflows. This dual-focus approach positions the company at the intersection of clinical drug development and enterprise artificial intelligence solutions for the biotech industry. Headquartered in Arlington, Massachusetts and founded in 2009, Kala Pharmaceuticals operates as both an ophthalmology-focused therapeutic developer and an emerging AI platform provider.
CEO Mr. Avi Minkowitz · 6 employees · United States · https://www.kalarx.com